GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

WGS GeneDx Holdings

Post-Mkt 08-05 19:13:29 EDT

69.91

-0.99

-1.40%

盘后70.00

+0.09+0.13%

17:52 EDT

High72.44	Low68.12	Vol867.11K
Open69.77	D1 Closing70.90	Amplitude6.09%
Mkt Cap2.07B	Tradable Cap1.33B	Total Shares29.68M
T/O60.96M	T/O Rate4.56%	Tradable Shares19.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"WGS","market":"US","secType":"STK","nameCN":"GeneDx Holdings","latestPrice":69.91,"timestamp":1785960000000,"preClose":70.9,"halted":0,"volume":867114,"hourTrading":{"tag":"盘后","latestPrice":70,"preClose":69.91,"latestTime":"17:52 EDT","volume":2402,"amount":167889.1111,"timestamp":1785966779455,"change":0.09,"changeRate":0.001287,"amplitude":0.007152},"delay":0,"changeRate":-0.013963328631876009,"floatShares":19015183,"shares":29675547,"eps":-3.639876,"marketStatus":"Post-Mkt","change":-0.99,"latestTime":"08-05 19:13:29 EDT","open":69.77,"high":72.44,"low":68.12,"amount":60958703.83752,"amplitude":0.060931,"askPrice":71.29,"askSize":28,"bidPrice":69.5,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.639876,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1785974400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":70.9,"preHourTrading":{"tag":"盘前","latestPrice":69.94,"preClose":70.9,"latestTime":"09:25 EDT","volume":572,"amount":40564.052672,"timestamp":1785936300175,"change":-0.96,"changeRate":-0.01354,"amplitude":0.055571},"postHourTrading":{"tag":"盘后","latestPrice":70,"preClose":69.91,"latestTime":"17:52 EDT","volume":2402,"amount":167889.1111,"timestamp":1785966779455,"change":0.09,"changeRate":0.001287,"amplitude":0.007152},"volumeRatio":0.606213,"impliedVol":0.7987,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/WGS/tweets","defaultTab":"tweets","newsList":[{"id":"2656539740","title":"GeneDx Holdings Price Target Maintained with a $90.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539740?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:25","pubTimestamp":1785835500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WGS/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656363575","title":"GeneDx Holdings Corp : Canaccord Genuity Raises Target Price to $90 from $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2656363575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656363575?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:36","pubTimestamp":1785832582,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4410J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530779","title":"GeneDx Holdings Corp Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530779","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530779?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:55","pubTimestamp":1785794119,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp reports results for the quarter ended June 30 - Earnings SummaryGeneDx Holdings CorpWGS.OQreported quarterly adjusted earnings of 1 cent per share for the quarter ended June 30, l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656307906","title":"CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307906","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307906?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:31","pubTimestamp":1785792666,"startTime":"0","endTime":"0","summary":"GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.19) by 105.26 percent. This is a 98 percent decrease over earnings of $0.50 per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60893338/correction-genedx-hldgs-q2-adj-eps-0-01-beats-0-19-estimate-sales-114-440m-beat-111-011m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656307981","title":"GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307981","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307981?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:24","pubTimestamp":1785792271,"startTime":"0","endTime":"0","summary":"GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301770","title":"GeneDx Q2 FY26 GAAP Net Loss Widens to $17.7 Million; Revenue Rises 11% Year over Year to $114.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301770","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301770?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:13","pubTimestamp":1785788007,"startTime":"0","endTime":"0","summary":"GeneDx Q2 FY26 GAAP net loss widens to $17.7 million; revenue rises 11% year over year to $114.4 millionGeneDx posted 2Q26 revenue of USD 114.4 million, up 11% year over year; GAAP net loss widened to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLbKRf0s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRVT","BX","BK4588","IE00BLSP4239.USD","IE00BLSP4452.SGD","GPZ","BK4196","BK4585","IE0004445239.USD","BK4135","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN8TJ469.HKD","IE00BGHQF748.EUR","PSP","WGS","IE00BBT3K403.USD","AAUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301205","title":"GeneDx Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301205","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301205?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:12","pubTimestamp":1785787943,"startTime":"0","endTime":"0","summary":"GeneDx Q2 revenue beats analyst estimatesOverviewU.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectationsAdjusted net income was $0.4 mln, up from a loss in the prio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","HELX","BK4139","PSCH","BK4196","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301935","title":"GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301935","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301935?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:09","pubTimestamp":1785787796,"startTime":"0","endTime":"0","summary":"GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/WGS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301592","title":"GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301592","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301592?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:06","pubTimestamp":1785787561,"startTime":"0","endTime":"0","summary":"BRIEF-GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 MillionAug 03 (Reuters) - GeneDx Q2 adjusted net income USD 400 thousand.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX2K43Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656462301","title":"GeneDx: Q3 2026 Revenue Guidance $122 Mln-$124 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2656462301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656462301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX2K43Q4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301122","title":"GeneDx Holdings: Reaffirmed Its Full Year 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301122","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301122?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX2K43Q4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656014613","title":"GeneDx Holdings Corp Q3 REV View $126.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2656014613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656014613?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX2K43Q4:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656730168","title":"Press Release: GeneDx Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656730168","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656730168?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"--  Reported second quarter 2026 revenue of $114.4 million, including. --  Reported exome and genome volume growth of 32% year-over-year. --  Reported adjusted gross margin of 70% and adjusted net income of. --  Reiterating full year 2026 revenue guidance of $475 to $490 million. with exome and genome volume growth of at least 30%. --  Exome and genome test revenue grew to $100.3 million, an increase of. 17% year-over-year.Exome and genome volume--  Exome and genome test result volume grew to 30,785, an increase of 32%. year-over-year.Gross margin--  Adjusted gross margin of 70% in the second quarter of 2026 is up from. 69% in the first quarter of 2026 and compares to 71% in the second. --  GAAP net loss was $17.7 million.Cash position--  Cash, cash equivalents, marketable securities and restricted cash was. --  Combined with the cash, cash equivalents, marketable securities","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLW","TLA","TSLO","TEST","07366","TSLY","TSDD","TSL","TSLQ","09766","WGS","09366","TSLS","TSLZ","TESL","TSLG","TSLL","TSLR","BK4196","07766","TSLP","TSYY","TSII","TSLT","CRSH","TSLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704717","title":"GeneDx Stock And 2 Testing Companies In Focus After Cyclospora Outbreak","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704717","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704717?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:27","pubTimestamp":1785176841,"startTime":"0","endTime":"0","summary":"The recent Cyclospora outbreak has pushed food safety, traceability, and testing to the top of investors’ watchlists. When regulators, distributors, and restaurant suppliers come under pressure, attention often shifts to companies that help monitor, test, and verify what moves through the food supply chain. This article looks at how that news may affect a handful of Food Safety & Testing Companies, and why some stocks could be positioned as potential beneficiaries of higher scrutiny and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-stock-and-2-testing-companies-in-focus-after-cyclospo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-stock-and-2-testing-companies-in-focus-after-cyclospo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BMED","PRE","BK4196","BLLN","WGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187157529","title":"Earning Preview: GeneDx Holdings Q2 revenue is expected to increase by 29.92%, and institutional views are cautiously optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=1187157529","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187157529?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:36","pubTimestamp":1785134178,"startTime":"0","endTime":"0","summary":"Abstract GeneDx Holdings will report quarterly results on August 03, 2026 Post Market; this preview compiles recent financial data and market expectations for revenue, profitability, and adjusted EPS...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: GeneDx Holdings Q2 revenue is expected to increase by 29.92%, and institutional views are cautiously optimistic","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097471","title":"How GeneDx’s Securities Lawsuit and Fabric Genomics Impairment Will Impact GeneDx Holdings (WGS) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097471","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654097471?lang=en_us&edition=fundamental","pubTime":"2026-07-27 13:20","pubTimestamp":1785129611,"startTime":"0","endTime":"0","summary":"Earlier in 2026, GeneDx Holdings Corp. was hit with a securities class action after reporting quarterly results that included a weaker adjusted gross margin, revenue shortfall versus estimates, lowered full‑year revenue guidance, and an impairment charge tied to its prior Fabric Genomics acquisition.\nThe combination of alleged disclosure failures and a write‑down on recently acquired technology raises fresh questions about GeneDx’s transparency, acquisition execution, and earnings quality...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/how-genedxs-securities-lawsuit-and-fabric-genomics-impairmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/how-genedxs-securities-lawsuit-and-fabric-genomics-impairmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","GXDW","BK4196","FEBU","VGFPF","PMDE","WGS","RGLO","DECU","VOTE","BK4211","JOYT","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652424499","title":"Genedx to Report Q2 2026 Results After Market Close, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2652424499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652424499?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:06","pubTimestamp":1784232375,"startTime":"0","endTime":"0","summary":"GeneDx to report Q2 2026 results after market close, host conference callGeneDx (WGS) schedules Q2 2026 financial results release for Aug. 3, 2026.Management conference call set for Aug. 3, 2026 at 4:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL5CvXT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650155631","title":"How Investors Are Reacting To GeneDx Holdings (WGS) Class Actions Over Fabric Impairment And Guidance Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2650155631","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650155631?lang=en_us&edition=fundamental","pubTime":"2026-07-11 11:38","pubTimestamp":1783741092,"startTime":"0","endTime":"0","summary":"In the past few weeks, multiple law firms have launched or promoted securities class actions against GeneDx Holdings, alleging that prior statements about the Fabric Genomics acquisition and its financial impact were false or misleading, particularly after the company disclosed a US$31.2 million impairment tied to Fabric alongside missed revenue estimates and reduced full-year guidance on May 4, 2026.\nThese lawsuits focus on whether GeneDx adequately disclosed Fabric’s business challenges...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/how-investors-are-reacting-to-genedx-holdings-wgs-class-acti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/how-investors-are-reacting-to-genedx-holdings-wgs-class-acti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","AGIX","VTHR","ISBC","AIPO","WGS","BK4196","ARTY","QTOC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647081377","title":"Genedx Holdings is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647081377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647081377?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:17","pubTimestamp":1782742620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WGS/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 10:17 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647022343","title":"Is GeneDx (WGS) Elevating Execution Risk or Opportunity With Its New Genomics-Focused President?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647022343","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647022343?lang=en_us&edition=fundamental","pubTime":"2026-06-29 03:09","pubTimestamp":1782673781,"startTime":"0","endTime":"0","summary":"GeneDx Holdings recently appointed Mark Gardner as President, effective June 15, 2026, reporting to CEO Katherine Stueland and leading the company’s commercial and operations teams to strengthen execution and scale genomic medicine offerings.\nGardner’s background running genomics and oncology businesses at Quest Diagnostics, OmniSeq, Thermo Fisher Scientific and Life Technologies adds deep operational and precision-medicine expertise to GeneDx’s leadership bench.\nWe’ll now examine how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/is-genedx-wgs-elevating-execution-risk-or-opportunity-with-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/is-genedx-wgs-elevating-execution-risk-or-opportunity-with-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4196","WGS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.genedx.com","stockEarnings":[{"period":"1week","weight":0.1458},{"period":"1month","weight":0.0502},{"period":"3month","weight":1.0426},{"period":"6month","weight":-0.1568},{"period":"1year","weight":-0.3456},{"period":"ytd","weight":-0.4549}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.104041},{"month":2,"riseRate":0.833333,"avgChangeRate":0.352675},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.143199},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.006052},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.040518},{"month":6,"riseRate":0.666667,"avgChangeRate":0.077733},{"month":7,"riseRate":0.666667,"avgChangeRate":0.106455},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.098735},{"month":9,"riseRate":0.2,"avgChangeRate":-0.072401},{"month":10,"riseRate":0.8,"avgChangeRate":0.18872},{"month":11,"riseRate":0.2,"avgChangeRate":-0.130294},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.04765}],"exchange":"NASDAQ","name":"GeneDx Holdings","nameEN":"GeneDx Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GeneDx Holdings,WGS,GeneDx Holdings股票,GeneDx Holdings股票老虎,GeneDx Holdings股票老虎国际,GeneDx Holdings行情,GeneDx Holdings股票行情,GeneDx Holdings股价,GeneDx Holdings股市,GeneDx Holdings股票价格,GeneDx Holdings股票交易,GeneDx Holdings股票购买,GeneDx Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}